Inclusion Criteria:  age 18 years or older, gender not limited; intravenous infusion requiring drug filtration, flow regulation, dosing and extension of infusion line; not participating in other clinical trials within one month; able to understand the purpose of the trial, voluntarily participate and sign the informed consent; willing to follow up and evaluate according to the requirements of the trial protocol.  Exclusion Criteria:  Patients with positive pregnancy test in women of childbearing age or lactating women; Patients with uncontrollable cardiomyopathy, heart failure and unable to tolerate infusion; Patients with uncontrollable decompensated renal function, especially in the anuric phase of acute renal failure and unable to tolerate infusion; Patients with uncontrollable extensive inflammation of the lung parenchyma, pulmonary congestion, pulmonary edema and unable to tolerate infusion; 0.2um size Test devices combined with any of the following drugs or preparations: fatty milk type, blood products type (blood cells, globulin, etc.), drugs that will produce insoluble precipitates with each other, etc.; 6, patients who are clinically infused with very small amounts of drugs (due to residual test line may reduce the amount of drugs delivered to patients); 7, puncture sites with inflammation, tumors, trauma, scars, etc.; 8, those who may be allergic to product materials; 9 Patients with AIDS;  10. Patients with mental disorders; 11. Other patients who are considered by the investigator to be unsuitable for participation in this study